RTHM vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 37)
RTHM logo

RTHM

EmergingHealthcare

Remote Patient Monitoring

RTHM is a remote patient monitoring platform that uses wearable devices and AI to track chronic disease patients between clinical visits, enabling proactive care intervention. HQ: San Francisco.

AI VisibilityBeta
Overall Score
D37
Category Rank
#484 of 596
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
37
Perplexity
37
Gemini
41

About

RTHM is a remote patient monitoring (RPM) company providing technology and clinical services to help healthcare providers track patients with chronic conditions between office visits. The platform uses FDA-cleared wearable devices to continuously or periodically measure vital signs, symptoms, and disease-specific biomarkers, transmitting data to a clinical monitoring center where RTHM's care team reviews alerts and communicates with patients experiencing concerning trends before they escalate to emergency care.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

37
Overall Score
90
#484
Category Rank
#2
88
AI Consensus
83
stable
Trend
up
37
ChatGPT
92
37
Perplexity
93
41
Gemini
89
36
Claude
96
37
Grok
95

Key Details

Category
Remote Patient Monitoring
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only RTHM
Remote Patient Monitoring

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.